Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors

Journal of Nuclear Medicine

Volumn 48, Issue 12, 2007, Pages 1932-1939

  Gerth, Hans U ^a   Juergens, Kai U ^a   Dirksen, Uta ^a   Gerss, Joachim ^a   Schober, Otmar ^a   Franzius, Christiane ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Ewing tumor; PET; PET CT; ROC analysis; Sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EWING SARCOMA; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; TUMOR BIOPSY; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; ROC CURVE; SARCOMA, EWING'S; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36949013885     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.045286     Document Type: Article

References (37)

1. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818-1829.
2. Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005;23:4354-4362.
3. Gerth HU, Rompel A, Krebs B, et al. Cytotoxic effects of novel polyoxotungstates and a platinum compound on human cancer cell lines. Anticancer Drugs. 2005;16:101-106.
4. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;20:694-701.
5. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18:3108-3114.
6. Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol. 1998;16:3044-3052.
7. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9:275-281.
8. MacVicar AD, Olliff JF, Pringle J, et al. Ewing sarcoma: MR imaging of chemotherapy-induced changes with histologic correlation. Radiology. 1992;184:859-864.
9. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
10. Hawkins DS, Rajendran JG, Conrad EU III, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D- glucose positron emission tomography [published erratum appears in Cancer. 2003;97:3130]. Cancer 2002;94:3277-3284.
11. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405-422.
12. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol. 2006;79:32-36.
13. Coleman RE, Delbeke D, Guiberteau MJ, et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med. 2005;46:1225-1239.
14. Wechalekar K, Sharma B, Cook G. PET/CT in oncology: a major advance. Clin Radiol. 2005;60:1143-1155.
15. 123I-MIBG SPECT/CT. J Nucl Med. 2006;47:1635-1642.
16. Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28:300-306.
17. 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr. 2006;30:689-694.
18. Franzius C, Juergens KU, Schober O. Is PET/CT necessary in paediatric oncology? For. Eur J Nucl Med Mol Imaging. 2006;33:960-965.
19. Hahn K, Pfluger T. Is PET/CT necessary in paediatric oncology? Against. Eur J Nucl Med Mol Imaging. 2006;33:966-968.
20. Kaste SC. Issues specific to implementing PET-CT for pediatric oncology: what we have learned along the way. Pediatr Radiol. 2004;34:205-213.
21. McCarville MB, Christie R, Daw NC, et al. PET/CT in the evaluation of childhood sarcomas. AJR. 2005;184:1293-1304.
22. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol. 2005;35:141-154.
23. Franzius C, Daldrup-Link HE, Wagner-Bohn A, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol. 2002;13:157-160.
24. Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol. 2001;12:479-486.
25. Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305-1311.
26. Gyorke T, Zajic T, Lange A, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun. 2006;27:17-24.
27. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828-8834.
28. 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005;46:587-595.
29. Even-Sapir E, Parag Y, Lerman H, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004;232:815-822.
30. G̈onen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001;221:763-767.
31. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
32. Starr SJ, Metz CE, Lusted LB, et al. Visual detection and localization of radiographic images. Radiology. 1975;116:533-538.
33. 18F-FDG PET/CT 1.0 [published erratum appears in J Nucl Med. 2006:47:903]. J Nucl Med. 2006;47:885-895.
34. Romer W, Nomayr A, Greess H, et al. Retrospective interactive rigid fusion of (18)F-FDG-PET and CT: additional diagnostic information in melanoma patients. Nuklearmedizin. 2006;45:88-95.
35. Lassmann M, Biassoni L, Monsieurs M, et al. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging. 2007;34:796-798.
36. International Commission on Radiological Protection. ICRP publication 80: radiation dose to patients from radiopharmaceuticals. In: Annals of the ICRP. Vol 28/3. New York, NY: Elsevier; 2000.
37. Wu TH, Chu TC, Huang YH, et al. A positron emission tomography/computed tomography (PET/CT) acquisition protocol for CT radiation dose optimization. Nucl Med Commun. 2005;26:323-330.